UNLABELLED: We hypothesized that (68)Ga-DOTATATE uptake of neuroendocrine tumors is sensitive to therapy with a nonradioactive somatostatin analog. METHODS: (68)Ga-DOTATATE PET/CT was used to examine 105 patients, 35 of whom had been pretreated with long-acting octreotide. The maximum standardized uptake value (SUV(max)) of target tissues, as well as metastases, was compared between the groups of patients with (group 1) and without (group 2) octreotide treatment. RESULTS: The SUV(max) of the spleen and liver was significantly lower in group 1 than in group 2 (both P < 0.001). There were no significant group differences in SUV(max) for primary tumors (28.6 ± 6.8 vs. 32.9 ± 31.5) or metastases in the liver (27.2 ± 14.8 vs. 25.7 ± 10.7), lymph nodes (41.4 ± 19.5 vs. 25.0 ± 6.3), or skeleton (39.5 ± 22.0 vs. 15.4 ± 7.8). In 9 patients available for intraindividual comparison, tumor uptake was unaffected by treatment with somatostatin analogs (21.7 vs. 20.6; P = 0.93). CONCLUSION: Treatment with a long-acting somatostatin analog did not significantly reduce (68)Ga-DOTATATE binding in neuroendocrine tumors but tended to improve the tumor-to-background ratio.
UNLABELLED: We hypothesized that (68)Ga-DOTATATE uptake of neuroendocrine tumors is sensitive to therapy with a nonradioactive somatostatin analog. METHODS: (68)Ga-DOTATATE PET/CT was used to examine 105 patients, 35 of whom had been pretreated with long-acting octreotide. The maximum standardized uptake value (SUV(max)) of target tissues, as well as metastases, was compared between the groups of patients with (group 1) and without (group 2) octreotide treatment. RESULTS: The SUV(max) of the spleen and liver was significantly lower in group 1 than in group 2 (both P < 0.001). There were no significant group differences in SUV(max) for primary tumors (28.6 ± 6.8 vs. 32.9 ± 31.5) or metastases in the liver (27.2 ± 14.8 vs. 25.7 ± 10.7), lymph nodes (41.4 ± 19.5 vs. 25.0 ± 6.3), or skeleton (39.5 ± 22.0 vs. 15.4 ± 7.8). In 9 patients available for intraindividual comparison, tumor uptake was unaffected by treatment with somatostatin analogs (21.7 vs. 20.6; P = 0.93). CONCLUSION: Treatment with a long-acting somatostatin analog did not significantly reduce (68)Ga-DOTATATE binding in neuroendocrine tumors but tended to improve the tumor-to-background ratio.
Authors: Rudolf A Werner; Heribert Hänscheid; Jeffrey P Leal; Mehrbod S Javadi; Takahiro Higuchi; Martin A Lodge; Andreas K Buck; Martin G Pomper; Constantin Lapa; Steven P Rowe Journal: Mol Imaging Biol Date: 2019-08 Impact factor: 3.488
Authors: E A Aalbersberg; B J de Wit-van der Veen; M W J Versleijen; L J Saveur; G D Valk; M E T Tesselaar; M P M Stokkel Journal: Eur J Nucl Med Mol Imaging Date: 2018-08-10 Impact factor: 9.236
Authors: Samira M Sadowski; Vladimir Neychev; Corina Millo; Joanna Shih; Naris Nilubol; Peter Herscovitch; Karel Pacak; Stephen J Marx; Electron Kebebew Journal: J Clin Oncol Date: 2015-12-28 Impact factor: 44.544
Authors: Ken Herrmann; Johannes Czernin; Edward M Wolin; Pawan Gupta; Martin Barrio; Antonio Gutierrez; Christiaan Schiepers; Sherly Mosessian; Michael E Phelps; Martin S Allen-Auerbach Journal: J Nucl Med Date: 2014-12-11 Impact factor: 10.057
Authors: Manuel Weber; Lukas Kessler; Benedikt Schaarschmidt; Wolfgang Peter Fendler; Harald Lahner; Gerald Antoch; Lale Umutlu; Ken Herrmann; Christoph Rischpler Journal: BMC Cancer Date: 2020-04-16 Impact factor: 4.430
Authors: Christine Schmid-Tannwald; Christoph M Schmid-Tannwald; John N Morelli; Ralph Neumann; Alexander R Haug; Nathalie Jansen; Konstantin Nikolaou; Nicolai Schramm; Maximilian F Reiser; Carsten Rist Journal: Eur J Nucl Med Mol Imaging Date: 2013-03-05 Impact factor: 9.236
Authors: Pedram Heidari; Eric Wehrenberg-Klee; Peiman Habibollahi; Daniel Yokell; Matthew Kulke; Umar Mahmood Journal: Cancer Res Date: 2013-09-30 Impact factor: 12.701